Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-factor prothrombin complex concentrate (4F-PCC) is a blood-derived coagulation factor replacement product containing the vitamin K-dependent factors II, VII, IX, and X, along with the anticoagulant proteins C and S. It is designed to rapidly restore hemostasis in patients with acquired coagulation factor deficiencies. In clinical trials sponsored by Janssen Research & Development, LLC, 4F-PCC was utilized as a reversal agent to evaluate its ability to counteract the anticoagulant effects of JNJ-64179375, a monoclonal antibody targeting thrombin exosite 1. The study aimed to establish a safety profile and a management strategy for potential bleeding events associated with the novel antithrombotic agent. 4F-PCC is typically administered intravenously and provides a more rapid reversal of anticoagulation compared to plasma or vitamin K alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-factor prothrombin complex concentrate.